PL378035A1 - Transdermalny system terapeutyczny w postaci plastra odporny na działanie promieniowania UV - Google Patents

Transdermalny system terapeutyczny w postaci plastra odporny na działanie promieniowania UV

Info

Publication number
PL378035A1
PL378035A1 PL378035A PL37803504A PL378035A1 PL 378035 A1 PL378035 A1 PL 378035A1 PL 378035 A PL378035 A PL 378035A PL 37803504 A PL37803504 A PL 37803504A PL 378035 A1 PL378035 A1 PL 378035A1
Authority
PL
Poland
Prior art keywords
absorber
transdermal therapeutic
active substance
matrix containing
matrix
Prior art date
Application number
PL378035A
Other languages
English (en)
Other versions
PL219030B1 (pl
Inventor
Jochen Schumacher
Manfred Süsse
Michael Dittgen
Stephan Mletzko
Jan-Peter Ingwersen
Thomas Langguth
Dirk Schenk
Hubert Kaffl
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03003888A external-priority patent/EP1449526A1/de
Priority claimed from EP03004061A external-priority patent/EP1452173A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of PL378035A1 publication Critical patent/PL378035A1/pl
Publication of PL219030B1 publication Critical patent/PL219030B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Wynalazek dotyczy transdermalnego systemu terapeutycznego (ang. Transdermal therapeutic system, w skrócie TTS) odpornego na działanie promieniowania UV, który to system obejmuje warstwę podkładową, przynajmniej jedną matrycę zawierającą substancję czynną oraz ewentualnie usuwaną folię i absorber promieniowania UV. Między warstwą podkładową a matrycą zawierającą substancję czynną, która to matryca oddalona jest w maksymalnym stopniu od powierzchni skóry, rozmieszczona jest przynajmniej jedna warstwa klejąca, w skład której wchodzi wspomniany absorber promieniowania UV, zaś między warstwą klejącą, w skład której wchodzi absorber promieniowania UV, a matrycą zawierającą substancję czynną, która to matryca oddalona jest w maksymalnym stopniu od powierzchni skóry, znajduje się przynajmniej jedna warstwa rozdzielcza, nieprzepuszczalna dla substancji czynnej oraz absorbera promieniowania UV. Transdermalny system terapeutyczny według wynalazku odznacza się wysoką stabilnością, zarazem nie powodując niedogodności typowych dla systemów TTS zawierających substancje czynne wrażliwe na działanie światła.
PL378035A 2003-02-21 2004-02-04 Transdermalny system terapeutyczny w postaci plastra odporny na działanie promieniowania UV PL219030B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003888A EP1449526A1 (de) 2003-02-21 2003-02-21 UV-stabiles transdermales Pflaster
EP03004061A EP1452173A1 (de) 2003-02-25 2003-02-25 UV-stabiles transdermales Pflaster

Publications (2)

Publication Number Publication Date
PL378035A1 true PL378035A1 (pl) 2006-02-20
PL219030B1 PL219030B1 (pl) 2015-03-31

Family

ID=32910125

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378035A PL219030B1 (pl) 2003-02-21 2004-02-04 Transdermalny system terapeutyczny w postaci plastra odporny na działanie promieniowania UV

Country Status (31)

Country Link
US (3) US8486443B2 (pl)
EP (1) EP1594483B1 (pl)
JP (1) JP4528296B2 (pl)
KR (1) KR100704825B1 (pl)
AR (1) AR043248A1 (pl)
AT (1) ATE333271T1 (pl)
AU (1) AU2004212675B2 (pl)
BR (1) BRPI0407615B8 (pl)
CA (1) CA2515918C (pl)
CR (1) CR7952A (pl)
CY (1) CY1105716T1 (pl)
DE (1) DE502004000988D1 (pl)
DK (1) DK1594483T3 (pl)
EA (1) EA008098B1 (pl)
EC (1) ECSP056030A (pl)
ES (1) ES2270345T3 (pl)
HK (1) HK1085394A1 (pl)
HR (1) HRP20050828B1 (pl)
IL (1) IL170295A (pl)
IS (1) IS2541B (pl)
ME (2) MEP14008A (pl)
MX (1) MXPA05008778A (pl)
NO (1) NO336108B1 (pl)
NZ (1) NZ541807A (pl)
PE (1) PE20041028A1 (pl)
PL (1) PL219030B1 (pl)
PT (1) PT1594483E (pl)
RS (1) RS50428B (pl)
SI (1) SI1594483T1 (pl)
UY (1) UY28189A1 (pl)
WO (1) WO2004073696A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004212675B2 (en) 2003-02-21 2006-06-01 Bayer Intellectual Property Gmbh UV stable transdermal therapeutic plaster
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
KR20070053267A (ko) * 2004-08-20 2007-05-23 쓰리엠 이노베이티브 프로퍼티즈 컴파니 반투명 보호 필름을 갖는 경피 약물 전달 장치
EP1719504A1 (de) * 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
US20100008966A1 (en) * 2008-07-14 2010-01-14 Surmodics, Inc. Medical Devices and Methods for Delivery of Nucleic Acids
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
HUE031326T2 (hu) * 2010-09-06 2017-07-28 Bayer Ip Gmbh Alacsony dózisú transzdermális tapaszok magas hatóanyagleadással
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
SG11201805570WA (en) 2015-12-30 2018-07-30 Corium Int Inc Systems and methods for long term transdermal administration
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
DE102020104907A1 (de) * 2020-02-25 2021-08-26 Berliner Glas GmbH Verfahren zur Herstellung eines Bauelements durch atomares Diffusionsbonden

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939827A (ja) 1982-08-27 1984-03-05 Nitto Electric Ind Co Ltd 医療用外用部材
JPS6069014A (ja) 1983-09-27 1985-04-19 Nitto Electric Ind Co Ltd 皮膚疾患治療用貼付剤
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
JPS60166611A (ja) 1984-02-10 1985-08-29 Nitto Electric Ind Co Ltd 疾患治療用部材
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
CH674618A5 (pl) 1987-04-02 1990-06-29 Ciba Geigy Ag
US5538736A (en) * 1987-04-28 1996-07-23 Lts Lohmann Therapie-Systeme Gmbh Active substance-containing plaster for the controlled administration of active substances to the skin
US5128284A (en) * 1987-10-23 1992-07-07 Allied-Signal Inc. Preparation of lanthanum chromite powders by sol-gel
DE58909570D1 (de) * 1988-10-27 1996-02-22 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
ES2081458T3 (es) * 1990-03-30 1996-03-16 Ciba Geigy Ag Composicion de pintura.
CA2066249C (en) * 1990-05-17 1997-12-16 Akira Nakagawa Estradiol percutaneous administration preparations
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
PT99338A (pt) 1990-10-29 1992-10-30 Alza Corp Processo para a preparacao de composicoes de farmacos anticoncepcionais administradas transdermicamente contendo uma mistura dum estrogeno e gestodeno e dispositivos para a sua administracao transdermica
JP3112707B2 (ja) 1991-07-25 2000-11-27 日本電気株式会社 監視システム用ポーリング方式
DE4336557C2 (de) * 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4336299A1 (de) 1993-10-25 1995-05-11 Arbo Robotron Medizin Technolo Gelkörper zur percutanen Verabreichung, insbesondere von Medikamenten
DE4403487C2 (de) * 1994-02-04 2003-10-16 Lohmann Therapie Syst Lts Arznei-Pflaster mit UV-vernetzbaren Acrylat-Copolymeren
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
AU692944B2 (en) 1994-11-18 1998-06-18 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbable patch
JP3908795B2 (ja) * 1994-11-29 2007-04-25 久光製薬株式会社 ケトチフェン含有経皮投与製剤
CN1188189C (zh) 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
JP3626275B2 (ja) 1996-04-09 2005-03-02 Ｊｓｒ株式会社 光硬化性樹脂組成物
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
JP4346696B2 (ja) 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP3434135B2 (ja) 1996-07-11 2003-08-04 アルパイン株式会社 ナビゲーション装置
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
JPH10265371A (ja) 1997-03-25 1998-10-06 Sekisui Chem Co Ltd 経皮吸収貼付剤
WO1998046267A1 (fr) 1997-04-16 1998-10-22 Hisamitsu Pharmaceutical Co., Inc. Composition de base pour absorption percutanee, preparation destinee a cette absorption et renfermant ladite composition
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
JP4399044B2 (ja) 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
AU3478200A (en) 1999-02-02 2000-08-25 Ortho-Mcneil Pharmaceutical, Inc. Method of manufacture for transdermal matrices
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE19912623A1 (de) 1999-03-20 2000-09-28 Lohmann Therapie Syst Lts Verfahren zur Erhöhung der Stabilität bei Lagerung und/oder Anwendung lichtempfindlicher therapeutischer Systeme oder deren Bestandteile
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
EP1197212A4 (en) 1999-07-01 2004-06-02 Hisamitsu Pharmaceutical Co ADHESIVE COMPOSITION FOR PERCUTANE ABSORPTION
BR0015802B1 (pt) 1999-11-24 2014-04-29 Agile Therapeutics Inc Sistema de administração de contraceptivo transdérmico, e, método para produzir um sistema de administração de contraceptivo transdérmico
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
PT1269999E (pt) * 2000-03-17 2013-06-11 Hisamitsu Pharmaceutical Co Penso com blindagem aos ultravioletas
BR0111580A (pt) * 2000-06-13 2003-09-16 Hisamitsu Pharmaceutical Co Curativo
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
TWI287455B (en) * 2000-12-05 2007-10-01 Noven Pharma Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
CA2478206A1 (en) 2002-03-11 2003-09-25 Patrick Michel Caubel Sulfatase inhibiting continuous progestogen contraceptive regimens
US6872401B2 (en) 2002-03-28 2005-03-29 L'oreal Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil
US7470452B1 (en) * 2002-06-13 2008-12-30 E. I. Du Pont De Nemours & Company Process for multilayer coating of substrates
US7032980B2 (en) * 2002-06-27 2006-04-25 The Little Tikes Company Non-slip wheel for a child's toy
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
EP1452173A1 (de) 2003-02-25 2004-09-01 Schering AG UV-stabiles transdermales Pflaster
AU2004212675B2 (en) 2003-02-21 2006-06-01 Bayer Intellectual Property Gmbh UV stable transdermal therapeutic plaster
US8524272B2 (en) * 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
EP1660294B1 (en) * 2003-08-25 2008-12-03 BFS Diversified Products, LLC Method and apparatus to monitor the compressive strength of insulation boards
MXPA06002754A (es) * 2003-09-11 2006-06-14 Ciba Sc Holding Ag Formas de producto concentrado basado en agua de estabilizadores de luz elaborados por una tecnica de polimerizacion de heterofase.
US20050129756A1 (en) 2003-12-10 2005-06-16 Hans-Peter Podhaisky UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
JP4965263B2 (ja) 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
UA89766C2 (en) 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
JP4504109B2 (ja) 2004-06-15 2010-07-14 株式会社新陽社 画像表示装置及び画素構成体
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
EP1719504A1 (de) 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
KR20110082142A (ko) 2008-10-06 2011-07-18 밀란 테크놀로지즈 인코포레이티드 비정질 로티고틴 경피 시스템

Also Published As

Publication number Publication date
NZ541807A (en) 2009-07-31
RS50428B (sr) 2009-12-31
BRPI0407615A (pt) 2006-02-14
PE20041028A1 (es) 2005-02-18
UY28189A1 (es) 2004-04-30
US20130226113A1 (en) 2013-08-29
PT1594483E (pt) 2006-12-29
HRP20050828B1 (hr) 2013-10-25
US20060251707A1 (en) 2006-11-09
US8486443B2 (en) 2013-07-16
EP1594483A1 (de) 2005-11-16
AU2004212675B2 (en) 2006-06-01
MEP14008A (en) 2010-06-10
AU2004212675A1 (en) 2004-09-02
SI1594483T1 (sl) 2006-12-31
ATE333271T1 (de) 2006-08-15
JP4528296B2 (ja) 2010-08-18
JP2006518348A (ja) 2006-08-10
ME00147B (me) 2010-10-10
DK1594483T3 (da) 2006-11-20
KR100704825B1 (ko) 2007-04-09
EP1594483B1 (de) 2006-07-19
NO336108B1 (no) 2015-05-18
US9095691B2 (en) 2015-08-04
DE502004000988D1 (de) 2006-08-31
BRPI0407615B1 (pt) 2018-02-14
CR7952A (es) 2006-02-06
IL170295A (en) 2010-05-31
AR043248A1 (es) 2005-07-20
IS8031A (is) 2005-09-15
IS2541B (is) 2009-09-15
CY1105716T1 (el) 2010-12-22
WO2004073696A1 (de) 2004-09-02
CA2515918A1 (en) 2004-09-02
HRP20050828A2 (en) 2006-03-31
EA200501224A1 (ru) 2006-04-28
PL219030B1 (pl) 2015-03-31
NO20054321L (no) 2005-09-20
MXPA05008778A (es) 2006-05-25
ECSP056030A (es) 2006-01-27
KR20050103499A (ko) 2005-10-31
CA2515918C (en) 2010-11-16
ES2270345T3 (es) 2007-04-01
HK1085394A1 (en) 2006-08-25
BRPI0407615B8 (pt) 2021-05-25
EA008098B1 (ru) 2007-02-27
RS20050639A (en) 2007-09-21
US20150335658A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
PL378035A1 (pl) Transdermalny system terapeutyczny w postaci plastra odporny na działanie promieniowania UV
AR097045A2 (es) Sistema terapéutico transdérmico
ES2581985T3 (es) Sistema terapéutico transdérmico que contiene norelgestromina para la contracepción y el reemplazo hormonal
DE50214184D1 (de) Transdermales therapeutisches system (tts) mit dem wirkstoff fentanyl
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
DK1381352T3 (da) Plaster til transdermal indgivelse af fentanyl
BRPI0719093B8 (pt) sistema transdérmico terapêutico com micro reservatórios de pares de ions
BR0313092A (pt) Sistema de liberação transdérmica aperfeiçoado
AR028525A1 (es) Sistema terapeutico transdermal para la administracion de lerisetron
ATE507831T1 (de) Melatonin enthaltende pharmazeutische formulierung
CY1115757T1 (el) Στερεο διαδερμικο θεραπευτικο συστημα που περιλαμβανει uv-απορροφητη
IS6172A (is) Notkun melatoníns til lækninga
DK1318830T3 (da) Konstitutivt aktiv form af Notch1-receptor eller et anti-Notch1-receptor til behandling af prostatacancer
DK1587500T3 (da) Forbindelser til oral dosering af et aktivt stof, der kræver smagsmaskering
UA87291C2 (ru) Пероральное пленкообразное лекарственное средство дезоксипеганина и способ его применения
DK1404341T3 (da) Kombination af aktive substanser til farmakologisk terapi af nikotinafhængighed
ATE529099T1 (de) Pharmazeutische einzeldosisform
AR037405A1 (es) Sistema terapeutico transdermal para la administracion de 17alfa-estradiol
CU23518A3 (es) Sistema terapéutico transdérmico estable a los rayos ultravioletas
ATE303135T1 (de) Pharmazeutische formulierungen zur gesteuerten freisetzung von 4-amino-6,7-dimethoxy-2-(5-
CY1114057T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση ριβαστιγμινης
FIU20020437U0 (fi) Leikkopuun jalka
TH87440B (th) ระบบรักษาโรคผ่านทางผิวหนังชนิดของแข็งที่มีสารดูดกลืนยูวี